Advances in Healthcare Technology and Osteoarthritis Drug Therapies Propel Two Healthcare Stocks

NEW YORK, NY / ACCESSWIRE / March 24, 2017 / HTG Molecular found it has passed the necessary technical feasibility tests for its technology to be adopted by a major scientific equipment distributor, while Flexion Therapeutics attracted a major pharmaceutical company’s attention with its OA drug. Rumors of a buyout float around investor circles.

RDI Initiates
Coverage:

HTG Molecular
Diagnostics Inc. https://ub.rdinvesting.com/news/?ticker=HTGM

Flexion Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=FLXN

It has been a busy last few weeks for HTG Molecular Diagnostics, and it saw its stock rise spectacularly on Thursday. The company saw its stock shoot up to $3.93 a share on Thursday, up $1.79. After hours trading continued its ascent, and is definitely a stock to watch. An impressive volume of 45.45 shares were traded on Thursday, punctuating investor’s interest. The company provides instruments, reagents, and services to research companies for testing molecular profiling applications. Its HTG EdgeSeq technology has been reported as being successfully adapted to be use with the QIAGEN GeneReader NGS System. QIAGEN is into oncology business whose GeneReader system allows scientists to sequence multiple DNA samples. Earlier in the week, Investors were justifiably excited as the company’s earnings report date approached, and some added to their portfolios. HTG Molecular has reported net loss of $0.76 a share on revenue of $1.46 million reported for the fourth quarter of 2016 as compared to net loss of $0.83 a share on revenue of $1.22 million, reported in the same quarter prior year. The company had $11.8 million in cash, cash equivalents and short term investments as on December 31, 2016.

Access RDI’s HTG Molecular Research Report at: https://ub.rdinvesting.com/news/?ticker=HTGM

Flexion Therapeutics stock price rose by more than 33% on Thursday to close at $26.25 a share. The $6.57 gain was continued with additional gain in afterhours trading. Buyout rumors from Sanofi were being discussed in investor circles with offer of more than $1 billion, while there was also a speculation of a different type – that this was a false rise and the price would soon retreat. On March 9th, the company announced the plans for the launch of its plans for launching its primary product, Zilretta, in the 4th quarter of 2017. The drug treats osteoarthritis, and almost 700 patients have received the drug therapy thus far with satisfactory outcomes. In corporate news, Chief Financial Officer Frederick Driscoll is preparing to retire on March 31 of this year.

Access RDI’s Flexion Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=FLXN

Our Actionable Research on HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) and Flexion Therapeutics Inc. (NASDAQ: FLXN) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458078